Table 2. Demographics in 25 patients with late relapses of MGCT, by mode of detection.
| All | Symptoms | Routine | |
|---|---|---|---|
| n (%) | 25 (100) | 14 (56) | 11 (44) |
| Agea (years) | 30 (20–68) | 27 (20–48) | 36 (23–68) |
| Primary histology | |||
| Seminoma | 10 | 6 | 4 |
| Non-seminoma | 15 | 8 | 7 |
| UICC stage b | |||
| I | 3 | 2 | 1 |
| IS | 2 | 1 | 1 |
| II | 6 | 4 | 2 |
| III | 10 | 6 | 4 |
| Extragonadal | 4 | 1 | 3 |
| IGCCCGc category stage | |||
| Good | 11 | 7 | 3 |
| Intermediate | 5 | 2 | 4 |
| Poor | 3 | 1 | 2 |
| Chemotherapy in primary treatment | |||
| Seminoma | 3 | 1 | 2 |
| Nonseminoma | 14 | 7 | 7 |
| Months to relapsea | 55 (32–224) | 88 (40–224) | 41 (32–110) |
| Sites of relapse | |||
| Retroperitoneal | 9 | 6 | 3 |
| Mediastinum | 6 | 3 | 3 |
| Lung/pleura | 5 | 2 | 3 |
| Neck/supraclavicular | 3 | 1 | 2 |
| Retrocrural | 1 | 1 | |
| Pelvis | 3 | 2 | 1 |
| Number of relapse sites | 27d | 15d | 12d |
| Symptoms leading to unscheduled visit | |||
| Tiredness | 4 | ||
| Pain (back/abdominal) | 6 (3/3) | ||
| Dyspnoea | 2 | ||
| Peripheral oedema | 1 | ||
| Dysphagia | 1 | ||
| Findings at routine follow-up leading to diagnosis | |||
| Radiology (chest X-ray/CT-thorax) | 4 (3/1) | ||
| Elevated markers (AFP/HCG) | 4 (2/2) | ||
| Palpable masses (supraclv./pelvis) | 3 (2/1) | ||
| Diameter (mm)a | 35 (10–135) | 43 (11–135) | 20 (10–46) |
| Status | |||
| NEDe | 16 | 10 | 6 |
| DODe | 7 | 3 | 4 |
| DIDe | 2 | 1 | 1 |
a
Median (range).
b
International Union against cancer (Sobin and Wittekind, 2002).
c
International Germ Cell Consensus Classification Group (1997).
e
Status: NED alive, no evidence of disease; DOD, dead of disease (MGCT); DID, dead of intercurrent disease, tumour-free.